AAAAAA
Results: 26-50/80
Authors:
Segawa, D
Sjoquist, PO
Wang, QD
Gonen, A
Nordlander, M
Ryden, L
Citation: D. Segawa et al., Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: An experimental study with the ultrashort-acting calcium antagonist clevidipine, J CARDIO PH, 36(3), 2000, pp. 338-343
Authors:
Pernow, J
Bohm, F
Johansson, BL
Hedin, U
Ryden, L
Citation: J. Pernow et al., Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis, J CARDIO PH, 36, 2000, pp. S418-S420
Authors:
Verheugt, FWA
Martin, JF
Ryden, L
Citation: Fwa. Verheugt et al., European cardiology: 50 years, LANCET, 356(9230), 2000, pp. 671-672
Authors:
Ryden, L
Breithardt, G
Poole-Wilson, P
Citation: L. Ryden et al., European role in global cardiology, LANCET, 355(9198), 2000, pp. 149-150
Authors:
Moor, E
Blomback, M
Silveira, A
Wiman, B
Cederlund, K
Bergstrand, L
Ivert, T
Ryden, L
Hamsten, A
Citation: E. Moor et al., Haemostatic function in patients undergoing coronary artery bypass grafting: Peroperative perturbations and relations to saphenous vein graft closure, THROMB RES, 98(1), 2000, pp. 39-49
Authors:
Uretsky, BF
Thygesen, K
Armstrong, PW
Cleland, JG
Horowitz, JD
Massie, BM
Packer, M
Poole-Wilson, PA
Ryden, L
Citation: Bf. Uretsky et al., Acute coronary findings at autopsy in heart failure patients with sudden death - Results from the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial, CIRCULATION, 102(6), 2000, pp. 611-616
Authors:
Al-Khalili, F
Svane, B
Wamala, SP
Orth-Gomer, K
Ryden, L
Schenck-Gustafsson, K
Citation: F. Al-khalili et al., Clinical importance of risk factors and exercise testing for prediction ofsignificant coronary artery stenosis in women recovering from unstable coronary artery disease: The Stockholm Female Coronary Risk Study, AM HEART J, 139(6), 2000, pp. 971-978
Authors:
Ryden, L
Hobbs, FDR
Citation: L. Ryden et Fdr. Hobbs, Evidence-based management of heart failure: ACE inhibitors and AT(1) receptor blockers - Proceedings of a roundtable meeting held in New Orleans, USA, 6 March 1999 - Foreword, EUR H J SUP, 1(Q), 1999, pp. Q1-Q2
Authors:
Ryden, L
Citation: L. Ryden, A review of evidence of benefits from ACE inhibitors in heart failure compared with AT(1) receptor blockers and other therapies, EUR H J SUP, 1(Q), 1999, pp. Q3-Q6
Authors:
Ryden, L
Giles, TD
Hobbs, FDR
Maggioni, AP
Armstrong, P
Brilla, CG
Citation: L. Ryden et al., Putting evidence into practice - Discussion, EUR H J SUP, 1(Q), 1999, pp. Q14-Q16
Authors:
Ryden, L
Citation: L. Ryden, The reuse of devices in cardiology - Policy Conference at the European heart house, 5-6 February 1998 - Foreword, EUR H J SUP, 1(G), 1999, pp. G1-G1
Authors:
Lisspers, J
Hofman-Bang, C
Nordlander, R
Ryden, L
Sundin, O
Ohman, A
Nygren, A
Citation: J. Lisspers et al., Multifactorial evaluation of a program for lifestyle behavior change in rehabilitation and secondary prevention of coronary artery disease, SC CARDIOVA, 33(1), 1999, pp. 9-16
Authors:
Ryden, L
Citation: L. Ryden, Presidential address, EUR J HE FA, 1(1), 1999, pp. 5-5
Authors:
Cleland, JGF
Armstrong, P
Horowitz, JD
Massie, B
Packer, M
Poole-Wilson, PA
Ryden, L
Citation: Jgf. Cleland et al., Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study, EUR J HE FA, 1(1), 1999, pp. 73-79
Authors:
Ryden, L
Citation: L. Ryden, Results of the ATLAS study, INT J CL PR, 1999, pp. 17-18
Authors:
Kappenberger, LJ
Linde, C
Jeanrenaud, X
Daubert, C
McKenna, W
Meisel, E
Sadoul, N
Chojnowska, L
Guize, L
Gras, D
Aebischer, N
Gadler, F
Ryden, L
Citation: Lj. Kappenberger et al., Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy, EUROPACE, 1(2), 1999, pp. 77-84
Authors:
Shimizu, M
Sjoquist, PO
Wang, QD
Ryden, L
Citation: M. Shimizu et al., Effects of the angiotensin AT(1) receptor blocker candesartan on myocardial ischemic/reperfusion injury, J AM S NEPH, 10, 1999, pp. S137-S142
Authors:
Shimizu, M
Wang, QD
Sjoquist, PO
Ryden, L
Citation: M. Shimizu et al., The angiotensin II AT1 receptor antagonist candesartan at antihypertensiveplasma concentrations reduces damage induced by ischemia-reperfusion, CARDIO DRUG, 13(4), 1999, pp. 347-353
Authors:
Wikstrom, G
Malmberg, K
Ryden, L
Citation: G. Wikstrom et al., Improved knowledge of antidiabetic treatment - a necessity for the modern cardiologist, EUR HEART J, 20(6), 1999, pp. 403-405
Authors:
Ryden, L
Citation: L. Ryden, The past, the present and the future of the European Society of Cardiology, EUR HEART J, 20(5), 1999, pp. 319-321
Authors:
Hofman-Bang, C
Lisspers, J
Nordlander, R
Nygren, A
Sundin, O
Ohman, A
Ryden, L
Citation: C. Hofman-bang et al., Two-year results of a controlled study of residential rehabilitation for patients treated with percutaneous transluminal coronary angioplasty - A randomized study of a multifactorial programme, EUR HEART J, 20(20), 1999, pp. 1465-1474
Authors:
Stahle, A
Mattsson, E
Ryden, L
Unden, AL
Nordlander, R
Citation: A. Stahle et al., Improved physical fitness and quality of life following training of elderly patients after acute coronary events - A 1 year follow-up randomized controlled study, EUR HEART J, 20(20), 1999, pp. 1475-1484
Authors:
Ryden, L
Citation: L. Ryden, ACE inhibitors or AT(1) receptor blockers in heart failure?, EUR HEART J, 20(18), 1999, pp. 1287-1289
Authors:
Ryden, L
Schenck-Gustafsson, K
Citation: L. Ryden et K. Schenck-gustafsson, The careers of female cardiologists, EUR HEART J, 20(17), 1999, pp. 1219-1221
Authors:
Bassand, JP
Ryden, L
Citation: Jp. Bassand et L. Ryden, Guidelines: making the headlines or confined to the sidelines?, EUR HEART J, 20(16), 1999, pp. 1149-1151